GSK (LON:GSK – Get Rating) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft to a “buy” rating in a research report issued to clients and investors on Friday, March 17th, MarketBeat Ratings reports.
Other research analysts also recently issued research reports about the company. Credit Suisse Group reissued a “neutral” rating and set a GBX 1,510 ($18.54) target price on shares of GSK in a research note on Thursday, February 2nd. Shore Capital reiterated a “buy” rating on shares of GSK in a report on Friday, February 24th. The Goldman Sachs Group set a GBX 2,000 ($24.56) price objective on GSK in a research note on Monday, March 6th. JPMorgan Chase & Co. set a GBX 1,400 ($17.19) price objective on GSK in a report on Thursday, March 2nd. Finally, Jefferies Financial Group set a GBX 1,575 ($19.34) target price on GSK in a research note on Wednesday, February 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of GBX 1,573.33 ($19.32).
GSK Stock Performance
Shares of GSK opened at GBX 1,421.40 ($17.46) on Friday. The company has a debt-to-equity ratio of 207.87, a quick ratio of 0.73 and a current ratio of 0.91. GSK has a twelve month low of GBX 1,280.92 ($15.73) and a twelve month high of GBX 2,280.50 ($28.01). The firm has a market cap of £58.14 billion, a P/E ratio of 1,262.34, a PEG ratio of 1.08 and a beta of 0.27. The firm’s 50 day moving average price is GBX 1,434.11 and its two-hundred day moving average price is GBX 1,406.09.
Insider Transactions at GSK
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Should You Buy Before the Ex-Dividend Date or Wait?
- Want Diversified Exposure in the Regional Banks? Try These ETFs
- Dividends, Short-Term Pain, but Long-Term Gain?
- Initiated Dividends At World Fuel Services, Are They Sustainable?
- Can American Airlines Shake Off Enough Weight For Profit Takeoff?
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.